“…Traditionally, PCa diagnosis relied on systematic biopsies in patients with elevated prostate-specific antigen (PSA) levels, leading to the dual challenge of overdiagnosing clinically insignificant PCa and underdiagnosing clinically significant (cs) tumors. The advent of multiparametric (mp) magnetic resonance imaging (MRI) and the Prostate Imaging-Reporting and Data System (PIRADS) transformed PCa diagnosis, emphasizing targeted biopsies for potential csPCa based on mpMRI findings 2 .…”